Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial

Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, Lindsay N. Carpp, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team United States Government (USG) COVID-19 Immune Assays Team
doi: https://doi.org/10.1101/2023.10.15.23295628

Article Information

doi 
https://doi.org/10.1101/2023.10.15.23295628
History 
  • October 15, 2023.
Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.

Author Information

  1. Bo Zhang1,
  2. Youyi Fong1,2,
  3. Jonathan Fintzi3,
  4. Eric Chu4,
  5. Holly E. Janes1,2,
  6. Lindsay N. Carpp1,
  7. Avi Kenny5,
  8. Marco Carone5,
  9. David Benkeser6,
  10. Lars W. P. van der Laan7,
  11. Weiping Deng8,
  12. Honghong Zhou8,
  13. Xiaowei Wang8,
  14. Yiwen Lu1,
  15. Chenchen Yu1,
  16. Bhavesh Borate1,
  17. Christopher R. Houchens9,
  18. Karen Martins9,
  19. Lakshmi Jayashankar9,
  20. Chuong Huynh9,
  21. Carl J. Fichtenbaum10,
  22. Spyros Kalams11,
  23. Cynthia L. Gay12,
  24. Michele P. Andrasik1,
  25. James G. Kublin1,
  26. Lawrence Corey1,13,
  27. Kathleen M. Neuzil14,
  28. Frances Priddy8,
  29. Rituparna Das8,
  30. Bethany Girard8,
  31. Hana M. El Sahly15,
  32. Lindsey R. Baden16,
  33. Ruben O. Donis9,
  34. Richard A. Koup17,
  35. Peter B. Gilbert1,2,5,
  36. Dean Follmann3,*,
  37. United States Government (USG) COVID-19 Immune Assays Team§,
  38. Moderna, Inc. Team§,
  39. Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team§,
  40. USG/CoVPN Biostatistics Team§
  1. 1Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
  2. 2Public Health Sciences Division, Fred Hutchinson Cancer Center; Seattle, WA, USA
  3. 3Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  4. 4Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA
  5. 5Department of Biostatistics, University of Washington; Seattle, WA, USA
  6. 6Department of Biostatistics and Bioinformatics, Rollins School of Public Health, Emory University; Atlanta, GA, USA
  7. 7Department of Statistics, University of Washington; Seattle, Washington, USA
  8. 8Moderna, Inc.; Cambridge, MA, USA
  9. 9Biomedical Advanced Research and Development Authority; Washington, DC, USA
  10. 10Division of Infectious Diseases, Department of Medicine, University of Cincinnati; Cincinnati, Ohio, USA
  11. 11Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center; Nashville, TN, USA
  12. 12Department of Medicine, Division of Infectious Diseases, UNC HIV Cure Center, University of North Carolina at Chapel Hill School of Medicine; Chapel Hill, NC, USA
  13. 13Department of Laboratory Medicine and Pathology, University of Washington; Seattle, WA, USA
  14. 14Center for Vaccine Development and Global Health, University of Maryland School of Medicine; Baltimore, MD, USA
  15. 15Department of Molecular Virology and Microbiology, Baylor College of Medicine; Houston, TX, USA
  16. 16Brigham and Women’s Hospital; Boston, MA, USA
  17. 17Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health; Bethesda, MD, USA
  1. ↵*Corresponding author. Email: dfollmann{at}niaid.nih.gov
Back to top
Posted October 15, 2023.
Download PDF

Supplementary Material

Data/Code
Email
Omicron COVID-19 Immune Correlates Analysis of a Third Dose of mRNA-1273 in the COVE Trial
Bo Zhang, Youyi Fong, Jonathan Fintzi, Eric Chu, Holly E. Janes, Lindsay N. Carpp, Avi Kenny, Marco Carone, David Benkeser, Lars W. P. van der Laan, Weiping Deng, Honghong Zhou, Xiaowei Wang, Yiwen Lu, Chenchen Yu, Bhavesh Borate, Christopher R. Houchens, Karen Martins, Lakshmi Jayashankar, Chuong Huynh, Carl J. Fichtenbaum, Spyros Kalams, Cynthia L. Gay, Michele P. Andrasik, James G. Kublin, Lawrence Corey, Kathleen M. Neuzil, Frances Priddy, Rituparna Das, Bethany Girard, Hana M. El Sahly, Lindsey R. Baden, Ruben O. Donis, Richard A. Koup, Peter B. Gilbert, Dean Follmann, Moderna, Inc. Team, Coronavirus Vaccine Prevention Network (CoVPN)/Coronavirus Efficacy (COVE) Team, USG/CoVPN Biostatistics Team
medRxiv 2023.10.15.23295628; doi: https://doi.org/10.1101/2023.10.15.23295628
Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools

Subject Area